Evidence map›Paper›PMID 41512285›Full record

ArticleBioinformatics (Oxford, England)2026

PLXFPred: interpretable cross-attention networks with hierarchical fusion of multi-modal features for predicting protein-ligand interactions and affinities.

Jixiang Li, Ruilin Cai, Ziteng Wang, Ye Sun, Wenge Yang, Yonghong Hu

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jixiang LiCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, P. R. China.
Ruilin CaiCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, P. R. China.
Ziteng WangCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, P. R. China.
Ye SunState Key Laboratory of Materials-Oriented Chemical Engineering, Nanjing Tech University, Nanjing 211816, P. R. China.
Wenge YangCollege of Food Science and Light Industry, Nanjing Tech University, Nanjing 211816, P. R. China.
Yonghong HuState Key Laboratory of Materials-Oriented Chemical Engineering, Nanjing Tech University, Nanjing 211816, P. R. China.ORCID 0000-0002-8268-8763

Funding

National Natural Science Foundation of China provided 22378194
6 · The paper itself

Abstract

summaryAccurately predicting protein-ligand interactions and binding affinities is essential for advancing structural biology. Despite recent advancements in deep learning, achieving rapid and precise predictions remains a challenging task. Our approach, Protein-Ligand Cross-Modal Fusion Predictor (PLXFPred), extracts physicochemical properties from amino acid sequences and SMILES. Additionally, it leverages pre-trained models to derive high-dimensional features. GATv2 and BILSTM were used to process the structural and sequence features, respectively. The model's core involves fusing sequence and graph features via a cross-modal cross-attention mechanism, followed by a multi-modal hierarchical fusion strategy that integrates high-level graph, early fusion, and cross-fusion features. Residual connections and conditional domain adversarial learning improve generalization to previously unseen protein-ligand pairs. Compared to state-of-the-art models, PLXFPred demonstrates superior performance, reducing errors (RMSD, MAE, SD) by over 50%, while providing interpretable biological insights through attention weight visualization and SHAP analysis. AVAILABILITY AND IMPLEMENTATION: The resource codes are available at https://github.com/xiyuyangtuo/PLXFPred/.

Identifiers

PMID41512285
PMCPMC12936868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.